202 related articles for article (PubMed ID: 34980502)
21. Esthesioneuroblastoma (olfactory neuroblastoma) treated with 111In-octreotide and 177Lu-DOTATATE PRRT.
Makis W; McCann K; McEwan AJ
Clin Nucl Med; 2015 Apr; 40(4):317-21. PubMed ID: 25674857
[TBL] [Abstract][Full Text] [Related]
22. Olfactory neuroblastoma: a single-center experience.
König M; Osnes T; Jebsen P; Evensen JF; Meling TR
Neurosurg Rev; 2018 Jan; 41(1):323-331. PubMed ID: 28540633
[TBL] [Abstract][Full Text] [Related]
23. Clinical features and the molecular biomarkers of olfactory neuroblastoma.
Peng X; Liu Y; Peng X; Wang Z; Zhang Z; Qiu Y; Jin M; Wang R; Kong D
Pathol Res Pract; 2018 Aug; 214(8):1123-1129. PubMed ID: 29921494
[TBL] [Abstract][Full Text] [Related]
24. Clinical utility of somatostatin receptor scintigraphic imaging (octreoscan) in esthesioneuroblastoma: a case study and survey of somatostatin receptor subtype expression.
Rostomily RC; Elias M; Deng M; Elias P; Born DE; Muballe D; Silbergeld DL; Futran N; Weymuller EA; Mankoff DA; Eary J
Head Neck; 2006 Apr; 28(4):305-12. PubMed ID: 16470879
[TBL] [Abstract][Full Text] [Related]
25. Olfactory neuroblastoma: the University of Erlangen-Nuremberg experience 1975-2000.
Constantinidis J; Steinhart H; Koch M; Buchfelder M; Schaenzer A; Weidenbecher M; Iro H
Otolaryngol Head Neck Surg; 2004 May; 130(5):567-74. PubMed ID: 15138422
[TBL] [Abstract][Full Text] [Related]
26. Prognostic utility of Hyams histological grading and Kadish-Morita staging systems for esthesioneuroblastoma outcomes.
Bell D; Saade R; Roberts D; Ow TJ; Kupferman M; DeMonte F; Hanna EY
Head Neck Pathol; 2015 Mar; 9(1):51-9. PubMed ID: 24806334
[TBL] [Abstract][Full Text] [Related]
27. Esthesioneuroblastoma chemotherapy and radiotherapy for extensive disease: a case report.
Gupta S; Husain N; Sundar S
World J Surg Oncol; 2011 Oct; 9():118. PubMed ID: 21974776
[TBL] [Abstract][Full Text] [Related]
28. Survival outcomes for stage-matched endoscopic and open resection of olfactory neuroblastoma.
Harvey RJ; Nalavenkata S; Sacks R; Adappa ND; Palmer JN; Purkey MT; Schlosser RJ; Snyderman C; Wang EW; Woodworth BA; Smee R; Havas T; Gallagher R
Head Neck; 2017 Dec; 39(12):2425-2432. PubMed ID: 28945299
[TBL] [Abstract][Full Text] [Related]
29. Olfactory neuroblastoma: the long-term outcome and late toxicity of multimodal therapy including radiotherapy based on treatment planning using computed tomography.
Mori T; Onimaru R; Onodera S; Tsuchiya K; Yasuda K; Hatakeyama H; Kobayashi H; Terasaka S; Homma A; Shirato H
Radiat Oncol; 2015 Apr; 10():88. PubMed ID: 25888953
[TBL] [Abstract][Full Text] [Related]
30. Consolidating the Hyams grading system in esthesioneuroblastoma - an individual participant data meta-analysis.
Vuong HG; Ngo TNM; Dunn IF
J Neurooncol; 2021 May; 153(1):15-22. PubMed ID: 33770323
[TBL] [Abstract][Full Text] [Related]
31. Long-Term Prognostic Analysis after Endoscopic Endonasal Surgery for Olfactory Neuroblastoma: A Retrospective Study of 13 Cases.
Zhang L; Niu K; Zhu K; Xia C; Yan J; Zhao W; Wei J; Duan M; Zheng G
PLoS One; 2016; 11(11):e0166046. PubMed ID: 27806104
[TBL] [Abstract][Full Text] [Related]
32. Olfactory Neuroblastoma: Morphological Reappraisal and Molecular Insights with Quantum Leap in Clinical Perspectives.
Bell D; Brandea AI; Hanna EY
Curr Oncol Rep; 2023 Jan; 25(1):11-18. PubMed ID: 36449116
[TBL] [Abstract][Full Text] [Related]
33. Molecular Evidence for Olfactory Neuroblastoma as a Tumor of Malignant Globose Basal Cells.
Zunitch MJ; Fisch AS; Lin B; Barrios-Camacho CM; Faquin WC; Tachie-Baffour Y; Louie JD; Jang W; Curry WT; Gray ST; Lin DT; Schwob JE; Holbrook EH
Mod Pathol; 2023 May; 36(5):100122. PubMed ID: 36841178
[TBL] [Abstract][Full Text] [Related]
34. Proposal of a TNM classification-based staging system for esthesioneuroblastoma: More precise prediction of prognosis.
Sun M; Wang K; Qu Y; Zhang J; Zhang S; Chen X; Wang J; Wu R; Zhang Y; Yi J; Xiao J; Xu G; Huang X; Luo J
Head Neck; 2021 Apr; 43(4):1097-1104. PubMed ID: 33301222
[TBL] [Abstract][Full Text] [Related]
35. [The results of combined treatment patients with olfactory neuroblastoma in material of Cancer Center in Warsaw].
Jarząbski A; Kiprian D; Szutkowski Z; Kawecki A; Michalski W
Otolaryngol Pol; 2011 Sep; 65(5 Suppl):93-7. PubMed ID: 22000257
[TBL] [Abstract][Full Text] [Related]
36. Olfactory neuroblastoma behavior inside and outside the olfactory cleft.
Jankowski R; Russel A; Gallet P; Henrot P; Vignaud JM; Nguyen DT
Surg Radiol Anat; 2015 Jul; 37(5):507-15. PubMed ID: 25218517
[TBL] [Abstract][Full Text] [Related]
37. Clincopathological analysis of olfactory neuroblastoma.
Fukushima S; Sugita Y; Niino D; Mihashi H; Ohshima K
Brain Tumor Pathol; 2012 Oct; 29(4):207-15. PubMed ID: 22331316
[TBL] [Abstract][Full Text] [Related]
38. Comparing Kadish, TNM, and the modified Dulguerov staging systems for esthesioneuroblastoma.
Joshi RR; Husain Q; Roman BR; Cracchiolo J; Yu Y; Tsai J; Kang J; McBride S; Lee NY; Morris L; Ganly I; Tabar V; Cohen MA
J Surg Oncol; 2019 Jan; 119(1):130-142. PubMed ID: 30466166
[TBL] [Abstract][Full Text] [Related]
39. Frequent expression of somatostatin receptor 2a in olfactory neuroblastomas: a new and distinctive feature.
Czapiewski P; Kunc M; Gorczyński A; Haybaeck J; Okoń K; Reszec J; Lewczuk A; Dzierzanowski J; Karczewska J; Biernat W; Turri-Zanoni M; Castelnuovo P; Taverna C; Franchi A; La Rosa S; Sessa F; Klöppel G
Hum Pathol; 2018 Sep; 79():144-150. PubMed ID: 29807052
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of PD-1, CTLA-4, CD4, and CD8 expression in olfactory neuroblastoma.
Wu L; Liu H; Liu H
Clin Neuropathol; 2023; 42(2):47-53. PubMed ID: 36708210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
